Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in 2023.
This report was published in the December 2023 edition of The Journal of VitreoRetinal Diseases (JVRD), which is the peer-reviewed journal of the American Society of Retina Specialists (ASRS). In the article, “Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee“, medical researchers considered Syfovre eye injuries decreased vision for patients after Syfovre treatments. Specifically, they looked at the cases of 13 such Syfovre patients.
For this set of 13 cases where Syfovre eye injuries decreased vision for patients, the December 2023 ASRS ReST Committee report provided these findings:
- 11 eyes were diagnosed as having developed occlusive vasculitis after a Syfovre injection;
- 6 of 14 eyes (one of the 13 patients suffered Syofvre eye injury and decreased vision in both of her eyes) had significant vision loss, having lost more than 6 lines of vision; and,
- 2 eyes required enucleation, a surgical procedure that involves the removal of the entire eye.
And from the Abstract for that December 2023 JVRD article:
Conclusions: There is currently no known etiology for vasculitis in this series. Optimum treatment strategies remain unknown. Infectious etiologies should be considered, and corticosteroid treatments may hasten resolution of inflammatory findings. Continued treatment of affected patients with [Syfovre (pegcetacoplan)] should be avoided.
From this February 28, 2024, Fierce Pharma news report, “Apellis cites current challenges with Syfovre launch but bright prospects in the long term“, we get the most recent explanation from Apellis about what caused these 13 cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments:
As for Syfovre’s safety issue — which Apellis originally speculated was a needle problem for the injected drug — the company now “firmly” believes it is caused by a pre-existing allergy toward polyethylene glycol, Francois said. The incidence of users developing vasculitis remains at .01% per injection, the company said.
We are handling Syfovre drug injury lawsuits involving cases where Syfovre eye injuries decreased vision for patients. Those Syfovre lawsuits would be filed against Apellis Pharmaceuticals, not the patients’ ophthalmologists or retina specialists.
[View article at original source]Syfovre
Free Case Evaluation
Strictly Confidential, No Obligation